Goldman Sachs Healthcare Conference Mikael Dolsten M.D., Ph.D. June 14, 2017

Forward Looking Statements This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts, expected regulatory submissions and approvals and anticipated performance and potential of Pfizer's products and product candidates that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors that May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the US Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.

Strong Track Record of Product Approvals 22 Key Approvals (14 NME); 42 Pivotal Study Starts (2011 – YTD)

(As of May 2, 2017)

Phase 1 36

96 Total

214 Discovery Projects

Phase 2 17

Phase 3 32

Registration 11

Discovery Projects

Potential in 2017/18 for 15 Pivotal Studies & 10 Midsize Differentiated Approvals

(Adult / CAPiTA)

ANCHOR

ASSETS

2011-2017 Focus: Growing In-Market Anchors 1

W A V E

2018-2022 Focus: Delivering on Clinical Pipeline 2

W A V E

Vaccines: C. difficile, S. aureus & Pneumo Nextgen

Oncology: I-O Combos

Rare Disease: Gene Therapy

I&I: Next Generation JAK inhibitors

Internal Medicine: NASH, AD/PD

7 Property of Pfizer Inc. – For Internal Use Only

Vaccines 9. Clostridium Difficile

10. Staphylococcus Aureus

11. Pneumococcal Nextgen

Potential for up to 15 Blockbuster Approvals over next 5 Years Approximately half potentially receiving approval by 2020

NMEs & Combos Oncology

1. IO-IO: Doublet / Triplet

2. IO-Targeted / IO-Chemo

3. Targeted Cancer Agents

4. Ibrance Intermediate/High Risk eBC

5. Xtandi non meta. PROSPER/EMBARK

Inflammation & Immunology 6. JAK1 Atopic Dermatitis

7. JAK3, TYK2/JAK1 Alopecia

8. Xeljanz Psoriatic Arthritis & Ulcerative Colitis

Rare Disease & Internal Medicine 12. domagrozumab Duchenne

13. rivipansel Sickle Cell

14. tafamidis Cardiomyopathy

15. tanezumab Pain

Biosimilars Across Cancer & Inflammatory Diseases

Potential 2017/18 News Flow Xeljanz

PsA Action Date (US)

ertugliflozin T2D

Action Date (US)

Bosulif CML 1L

Action Date(US/EU)

Xeljanz UC

Action Date (US)

dacomitinib EGFR+ NSCLC

Submission(US/EU)

Sutent Adjuvant RCC

Action Date (US)

glasdegib + LDAC 1L AML Unfit

Submission(US/EU)

SPK-9001 Hemophilia B

Phase 1/2 Data

ACC, FK NASH

Phase 1 Data

Bavencio Doublets + 4-1BB,+OX-40 Phase 1/2 Data

p-Cadherin BiFx Cancer

Phase 1 Data

Bavencio Triplet + 4-1BB + OX-40

Phase 1 Data

2H 2017 1H 2018

LATE

STA

GE

EAR

LY S

TAG

E TFPI Hemophilia A&B

Phase 1 Data

Ibrance combo PDAC

Phase 1 Data

lorlatinib ALK+ NSCLC

Submission (US)

JAK1 Atopic Derm Phase 2 Data

Questions?